Astria Therapeutics, Inc. (ATXS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
100 High Street
Boston, MA 02110
United States of America (the)
Phone
617 349 1971
Website
Sector
Healthcare
Industry
Biotechnology
Employees
78
First IPO Date
June 25, 2015
| Name | Title | Pay | Year Born |
| Jill C. Milne | Co-Founder, Chief Executive Officer, President & Director | 967,338 | 1968 |
| Noah Clauser | Chief Financial Officer & Treasurer | 621,406 | 1973 |
| Benjamin S. Harshbarger | Chief Legal Officer | 658,041 | 1969 |
| Christopher J. Morabito | Chief Medical Officer | 690,824 | 1970 |
| John Ruesch | Senior Vice President of Pharmaceutical Sciences & Technical Operations | 0 | N/A |
| Andrea L. Matthews | Chief Business Officer | 0 | 1982 |
| Rafif Dagher | Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research | 0 | N/A |
| Keri McGrail | Chief Human Resources Officer | 0 | N/A |
| Andrew A. Komjathy | Chief Commercial Officer | 0 | 1963 |
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.